Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23489756 | 0.82 | APLNR (0.33) | — | |
| SCHEMBL22697019 | 0.82 | — | — | |
| SCHEMBL22570346 | 0.82 | — | — | |
| SCHEMBL26315298 | 0.82 | HDAC4 (0.31) | — | |
| SCHEMBL26313665 | 0.79 | HDAC4 (0.31) | — | |
| SCHEMBL20844090 | 0.79 | TSHR (0.35) | — | |
| SCHEMBL4546362 | 0.76 | P2RX3 (0.36) | P2RX3P2RX2 | |
| SCHEMBL26315300 | 0.76 | HDAC4 (0.30) | — | |
| SCHEMBL26463849 | 0.76 | CYP11B1 (0.38) | — | |
| SCHEMBL24054653 | 0.74 | GABRA1 (0.34) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2008082488-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-20070078152-A1 | Piperidine derivatives | AMGEN INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | P2RX3 186/4885P2RX2 280/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | P2RX3 2965/4885P2RX2 2352/4885 |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | P2RX3 2999/4885P2RX2 3128/4885 |
| US-20230203055-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF IN MEDICINE | VIP, CYP11B2, CYP11B1 | P2RX3 1918/4885P2RX2 1714/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | P2RX3 901/4885P2RX2 872/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | P2RX3 204/4885P2RX2 254/4885 |
| US-20080045501-A1 | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | AURKB, AURKC, AURKA | P2RX3 3707/4885P2RX2 3940/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | P2RX3 816/4885P2RX2 1110/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | P2RX3 2396/4885P2RX2 2566/4885 |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | P2RX3 2336/4885P2RX2 2105/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | P2RX3 439/4885P2RX2 627/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | P2RX3 4144/4885P2RX2 3899/4885 |
| US-20070078152-A1 | Piperidine derivatives | VIPR2, VIPR1, GRPR | P2RX3 109/4885P2RX2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.